Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diclofenac as a KMO Inhibitor in Alcohol Use Disorder
NCT06636227Phase 1Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Dec 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of diclofenac in alcohol use disorder (AUD) (4 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: Change in blood kynurenic acid (KYNA) levels at 5 weeks. Started Dec 2024; status: completed.
02
Drugs
diclofenac
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT06636227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06636227.